197 related articles for article (PubMed ID: 33177155)
1. PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
Su S; Chhabra G; Ndiaye MA; Singh CK; Ye T; Huang W; Dewey CN; Setaluri V; Ahmad N
Mol Cancer Ther; 2021 Jan; 20(1):161-172. PubMed ID: 33177155
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
3. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
[TBL] [Abstract][Full Text] [Related]
4. PLK1 targets NOTCH1 during DNA damage and mitotic progression.
De Blasio C; Zonfrilli A; Franchitto M; Mariano G; Cialfi S; Verma N; Checquolo S; Bellavia D; Palermo R; Benelli D; Screpanti I; Talora C
J Biol Chem; 2019 Nov; 294(47):17941-17950. PubMed ID: 31597699
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
6. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
7. Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
Gutteridge RE; Singh CK; Ndiaye MA; Ahmad N
Cancer Lett; 2017 May; 394():13-21. PubMed ID: 28235541
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
Harris PS; Venkataraman S; Alimova I; Birks DK; Donson AM; Knipstein J; Dubuc A; Taylor MD; Handler MH; Foreman NK; Vibhakar R
BMC Cancer; 2012 Mar; 12():80. PubMed ID: 22390279
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
10. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.
Kannan S; Aitken MJL; Herbrich SM; Golfman LS; Hall MG; Mak DH; Burks JK; Song G; Konopleva M; Mullighan CG; Chandra J; Zweidler-McKay PA
Mol Cancer Ther; 2019 Sep; 18(9):1615-1627. PubMed ID: 31227645
[TBL] [Abstract][Full Text] [Related]
11. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
12. PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors.
Pezuk JA; Valera ET; Brassesco MS
Curr Drug Targets; 2016; 17(14):1661-1672. PubMed ID: 26302797
[TBL] [Abstract][Full Text] [Related]
13. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
14. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
[TBL] [Abstract][Full Text] [Related]
15. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
17. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
18. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
Hugle M; Belz K; Fulda S
Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
20. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
